Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2009

Open Access 01-12-2009 | Research article

Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

Authors: Camiel Verhamme, Rob J de Haan, Marinus Vermeulen, Frank Baas, Marianne de Visser, Ivo N van Schaik

Published in: BMC Medicine | Issue 1/2009

Login to get access

Abstract

Background

High dose oral ascorbic acid substantially improved myelination and locomotor function in a Charcot-Marie-Tooth type 1A mouse model. A phase II study was warranted to investigate whether high dose ascorbic acid also has such a substantial effect on myelination in Charcot-Marie-Tooth type 1A patients and whether this treatment is safe.

Methods

Patients below age 25 years were randomly assigned to receive placebo or ascorbic acid (one gram twice daily) in a double-blind fashion during one year. The primary outcome measure was the change over time in motor nerve conduction velocity of the median nerve. Secondary outcome measures included changes in minimal F response latencies, compound muscle action potential amplitude, muscle strength, sensory function, Charcot-Marie-Tooth neuropathy score, and disability.

Results

There were no significant differences between the six placebo-treated (median age 16 years, range 13 to 24) and the five ascorbic acid-treated (19, 14 to 24) patients in change in motor nerve conduction velocity of the median nerve (mean difference ascorbic acid as opposed to placebo treatment of 1.3 m/s, confidence interval -0.3 to 3.0 m/s, P = 0.11) or in change of any of the secondary outcome measures over time. One patient in the ascorbic acid group developed a skin rash, which led to discontinuation of the study medication.

Conclusion

Oral high dose ascorbic acid for one year did not improve myelination of the median nerve in young Charcot-Marie-Tooth type 1A patients. Treatment was relatively safe.

Trial registration

Current Controlled Trials ISRCTN56968278, ClinicalTrials.gov NCT00271635.
Appendix
Available only for authorised users
Literature
1.
Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe A, Latour P, Le Guern E, Brice A, Mostacciuolo ML, Schiavon F, Palau F, Bort S, Upadhyaya M, Rocchi M, Archidiacono N, Mandich P, Bellone E, Silander K, Savontaus ML, Navon R, Goldberg-Stern H, Estivill X, Volpini V, Friedl W, Gal A, et al: Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996, 4: 25-33.PubMed
2.
Gabreëls-Festen AA, Joosten EM, Gabreëls FJ, Jennekens FG, Janssen-van Kempen TW: Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I). J Neurol Sci. 1992, 107: 145-154. 10.1016/0022-510X(92)90282-P.CrossRefPubMed
3.
Robaglia-Schlupp A, Pizant J, Norreel JC, Passage E, Saberan-Djoneidi D, Ansaldi JL, Vinay L, Figarella-Branger D, Levy N, Clarac F, Cau P, Pellissier JF, Fontés M: PMP22 overexpression causes dysmyelination in mice. Brain. 2002, 125: 2213-2221. 10.1093/brain/awf230.CrossRefPubMed
4.
Garcia A, Combarros O, Calleja J, Berciano J: Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study. Neurology. 1998, 50: 1061-1067.CrossRefPubMed
5.
Killian JM, Tiwari PS, Jacobson S, Jackson RD, Lupski JR: Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve. 1996, 19: 74-78. 10.1002/(SICI)1097-4598(199601)19:1<74::AID-MUS10>3.0.CO;2-3.CrossRefPubMed
6.
Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, Lewis RA, McDermott MP: Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. 2008, 70: 378-383. 10.1212/01.wnl.0000297553.36441.ce.CrossRefPubMed
7.
Verhamme C, van Schaik IN, Koelman JH, De Haan RJ, de Visser M: The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain. 2009.
8.
Berciano J, Garcia A, Calleja J, Combarros O: Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul Disord. 2000, 10: 419-424. 10.1016/S0960-8966(99)00114-5.CrossRefPubMed
9.
Verhamme C, van Schaik IN, Koelman JH, De Haan RJ, Vermeulen M, De Visser M: Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol. 2004, 251: 1491-1497. 10.1007/s00415-004-0578-x.CrossRefPubMed
10.
Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontes M: Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord. 2007, 17: 248-253. 10.1016/j.nmd.2006.12.008.CrossRefPubMed
11.
Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M: Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004, 10: 396-401. 10.1038/nm1023.CrossRefPubMed
12.
13.
van Dijk JG, Kamp van der WIM, van Hilten BJ, van Someren P: Influence of recording site on CMAP amplitude on its variation over a length of nerve. Muscle Nerve. 1994, 17: 1286-1292. 10.1002/mus.880171107.CrossRefPubMed
14.
Tjon-A-Tsien AM, Lemkes HH, Kamp-Huyts van der AJ, van Dijk JG: Large electrodes improve nerve conduction repeatability in controls as well as in patients with diabetic neuropathy. Muscle Nerve. 1996, 19: 689-695. 10.1002/(SICI)1097-4598(199606)19:6<689::AID-MUS1>3.0.CO;2-6.CrossRefPubMed
15.
Ploeg van der RJ, Fidler V, Oosterhuis HJ: Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry. 1991, 54: 244-247. 10.1136/jnnp.54.3.244.CrossRefPubMedPubMedCentral
16.
Solari A, Laura M, Salsano E, Radice D, Pareyson D: Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord. 2008, 18: 19-26. 10.1016/j.nmd.2007.09.006.CrossRefPubMed
17.
Merkies IS, Schmitz PI, Meché van der FG, van Doorn PA: Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 2000, 54: 943-949.CrossRefPubMed
18.
Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M: Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005, 64: 1209-1214.CrossRefPubMed
19.
Weisscher N, Post B, De Haan RJ, Glas CAW, Speelman JD, Vermeulen M: The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. Neurology. 2007, 69: 2155-2161. 10.1212/01.wnl.0000295666.30948.9d.CrossRefPubMed
20.
Merkies IS, Schmitz PI, Meche van der FG, Samijn JP, van Doorn PA: Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002, 72: 596-601. 10.1136/jnnp.72.5.596.CrossRefPubMedPubMedCentral
21.
22.
van Dijk JP, Blok JH, Lapatki BG, van Schaik IN, Zwarts MJ, Stegeman DF: Motor unit number estimation using high-density surface electromyography. Clinical Neurophysiology. 2008, 119: 33-42. 10.1016/j.clinph.2007.09.133.CrossRefPubMed
23.
Vickers AJ, Altman DG: Statistics Notes: Analysing controlled trials with baseline and follow up measurements. BMJ. 2001, 323: 1123-1124. 10.1136/bmj.323.7321.1123.CrossRefPubMedPubMedCentral
24.
Metz J, Hundertmark U, Pevny I: Vitamin C allergy of the delayed type. Contact Dermatitis. 1980, 6: 172-174. 10.1111/j.1600-0536.1980.tb05592.x.CrossRefPubMed
25.
Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM: Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009, 8: 537-544. 10.1016/S1474-4422(09)70108-5.CrossRefPubMed
26.
Toth C: Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurol Scand. 2009, 120: 134-8. 10.1111/j.1600-0404.2008.01134.x.CrossRefPubMed
27.
Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sabéran-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Fontés M: Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet. 1998, 7: 449-458. 10.1093/hmg/7.3.449.CrossRefPubMed
28.
Ginter E: Endogenous ascorbic acid synthesis and recommended dietary allowances for vitamin C. Am J Clin Nutr. 1981, 34: 1448-1451.PubMed
29.
Reilly MM, de JP, Pareyson D: 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A) 8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord. 2006, 16: 396-402. 10.1016/j.nmd.2006.03.008.CrossRefPubMed
Metadata
Title
Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial
Authors
Camiel Verhamme
Rob J de Haan
Marinus Vermeulen
Frank Baas
Marianne de Visser
Ivo N van Schaik
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2009
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-7-70

Other articles of this Issue 1/2009

BMC Medicine 1/2009 Go to the issue

Commentary

The economics of treating stroke as an acute brain attack

Commentary

Can we improve outcomes in AF patients by early therapy?

Research article

Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status

Review

Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review

Commentary

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

Research article

Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease